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Abstract: Drug development is a complicated, slow and expensive process with high failure rates.
One strategy to mitigate these factors is to recycle existing drugs with viable safety profiles and have
gained Food and Drug Administration approval following extensive clinical trials. Cardiovascular
and neurodegenerative diseases are difficult to treat, and there exist few effective therapeutics,
necessitating the development of new, more efficacious drugs. Recent scientific studies have led to
a mechanistic understanding of heart and brain disease progression, which has led researchers to
assess myriad drugs for their potential as pharmacological treatments for these ailments. The focus
of this review is to survey strategies for the selection of drug repurposing candidates and provide
representative case studies where drug repurposing strategies were used to discover therapeutics for
cardiovascular and neurodegenerative diseases, with a focus on anti-inflammatory processes where
new drug alternatives are needed.
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Drug development is a long, labor-intensive process with no guarantee of success.
On average, it takes 10 years and 2.6 billion dollars to develop a new drug, with success
rates averaging only about 12% [1]. One way to mitigate the barriers of drug development
is to repurpose drugs approved by the Food and Drug Administration (FDA) as well as
European Medicines Agency (EMA) for the treatment of different diseases. Drug repurposing is the practice of finding new uses for existing drugs at any stage of development.
The benefit of drug repurposing is that the risk of failure is significantly lower than drug
development, which permits more effective use of resources to optimize drug efficacy for
treatment of the desired ailment. Much of the primary research regarding repurposed
drug safety, mechanism, and dosage has already been completed when the drug was first
studied [2]. For example, a drug that demonstrated efficacy in animal models with low
side effects but failed in human clinical trials to perform its intended purpose, might be a
good candidate for use as a therapeutic for a different disease. Drugs with the potential
to be repurposed have progressed through many of the steps required to meet regulatory
safety and potency benchmarks, allowing for an accelerated and abbreviated path to FDA
approval. A few representative examples of successful drugs that have been repurposed
include amantadine, acetylsalicylic acid, cyclosporine, minoxidil, and imatinib (Table 1) [3].
Repurposed drugs are generally screened by computer search algorithms from databases of
therapeutics that may or may not have been sufficiently effective in providing treatment for
the pathology that served as their original target. For example, some drugs lack sufficient
drug-like qualities to warrant further investigation for treating an intended illness, but
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modification of the molecular scaffold or functional groups attached to the drug template
may afford attributes and activity suitable for therapeutic viability. The therapeutic index
for a repurposed drug requires investigation into dosage recommendations for maximal
benefit to counter the illness, while minimizing detrimental side-effects to the patient.
Table 1. Examples of some FDA-approved repurposed drugs.

Drug

Original Purpose

Repurposed Use

Reference

Amantadine

Parkinson’s disease

Influenza A

[4]

Acetylsalicylic acid

Inflammation, pain
relief

Antiplatelet

[5]

Cyclosporine

Rheumatoid arthritis

Transplant rejection,
psoriasis, chronic dry eye

[6]

Minoxidil

Hypertension

Alopecia

[7]

Imatinib

Chronic myelogous
leukemia

Gastrointestinal stromal
tumor

[8]

1.1. Technology to Repurpose Drugs
Computational screening of previously marketed drugs to identify drug repurposing
candidates can lead researchers to initiate new clinical trials for the treatment of alternative
ailments. Multiple computational strategies have emerged to identify potential candidates
for drug repurposing. Of these, four strategies have gained popularity in recent years and
will be discussed in brief. These strategies are side effect similarity mapping, genome-wide
association studies (GWAS), small-molecule peptide-influenced drug repurposing (SPIDR),
and computational high-throughput screening (HTS) [9–11].
In side-effect similarity mapping, existing drugs are categorized by their side effects
using the Unified Medical Language System (UMLS) ontology for medical symptoms.
Developed by Campillos et al. (2008), 746 marketed drugs were organized according to
their listed phenotypic side effect similarities rather than a chemical similarity, and 20 of
these marketed drugs were confirmed through in vitro assays to indicate that side effect
similarity may be indicative of common protein targets. Using this strategy, prediction
of the likelihood that two drugs had the same target based on their side effects was
demonstrated [12]. This study describes a process by which drugs marketed for different
targets could be identified as having potential for repurposing.
GWAS identifies single nucleotide polymorphisms (SNPs) and their associated phenotypes for individuals with a given disease. GWAS is performed by genotyping individuals
who share a common disease and determining whether a genetic variant is shared to statistical significance among this population. Experimental validation by chromatin precipitation
is then performed and variants are associated with phenotypic effects [13]. This technique
has been used to identify many novel variants to trait associations in a variety of diseases
such as macular degeneration, anorexia nervosa, depression, coronary artery disease and
diabetes mellitus, and can be used to determine novel drug targets as well [13,14]. For
example, GWAS have been used to identify SNPs for Parkinson’s disease (PD) and determined that estradiol may protect dopaminergic neurons in PD. This supported previous
evidence that estradiol may be protective against PD because men are more likely to be
diagnosed [15]. The neuroprotective role of estradiol was later confirmed in in vivo studies.
At present, estradiol is still not an approved treatment for PD, but efficacy studies are
ongoing [2,16,17]. Another example of GWAS being useful for determining novel drug
targets was the identification of a gene encoding a disintegrin and metalloproteinase with
thrombospondin motifs TS7 (ADAMTS7), a gene implicated in coronary artery disease
(CAD) for its presence in angiographic CAD patients and role in smooth muscle cell migration, a finding that supports the idea of genetically inherited CAD [16,18]. Using GWAS, it
is possible to identify new potential targets based on SNPs.
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SPIDR is a recently developed computational screening technique to identify drugs
that can target a specific receptor by looking at its peptide ligand conformational space [11].
This method was integrated into the free program DockoMatic v 2.1, making this process
accessible to lower-resourced institutions [17]. This technique works by first utilizing the
genetic algorithm managed peptide mutant screening (GAMPMS) to search for peptide
mutants with high binding affinity to the receptor, and then this population of peptides
is moved over to the SimSearcher utility to identify the best small molecules analogous
to the peptide population for binding to the isoform [11]. SPIDR was developed and
used to find 12 small molecules computationally predicted to bind with high affinity to
a nicotinic acetylcholine receptor (nAChR) isoform associated with Alzheimer’s and PD,
by looking at α-conotoxin MII peptide analogs that would bind favorable to the receptor
isoform specifically [11]. Following this publication, a qualitative assay to detect dopamine
release by ligand action on nAChRs was developed with the intent to assess bioactivity of
molecules that may act on different nAChR isoforms for drug development. This assay
was created using a luminescence-based assay and validated with known nAChR binders:
acetylcholine, nicotine and cytosine [19]. The PC-12 cell-based assay was intended to be
used to test the small molecules found in the SPIDR development publication for nAChR
activity as an in vitro validation for the SPIDR methodology.
Additionally, small molecule compound screens can be used to identify drugs amenable
to being repurposed. Computational programs such as AutoDock Vina are often used to
screen molecular library databases like ZINC, chEMBL, PubChem, DrugBank, and others [20–22]. Computational screens of small molecule databases are an ideal starting point
for any drug discovery project to narrow down a list of compounds that may bind a biological target with high affinity. However, wet lab experimentation needs to be conducted,
which can be done with commercially available libraries of drugs using in vitro cell-based
assays. Researchers study whether a drug induces a phenotypic effect in cell-based assays,
which are usually performed in cell culture or on a model organism whereas a target-based
screen can be performed in vitro using techniques like enzyme-linked immunosorbent
assay (ELISA), Surface Plasmon Resonance (SPR) or Nuclear Magnetic Resonance (NMR)
spectroscopy. Many reviews have been recently published on the topic of drug repurposing in either CVD or neurodegeneration [23–29]. However, there is little explored in the
realm of drugs that may be repurposed to target inflammatory processes which link these
two diseases. In this article, we will briefly discuss strategies for repurposing drugs and
examples of drugs that are being repurposed for treatment of cardiovascular disease and
neurodegenerative disorders. Specifically, we will cover those conditions that affect both
cardiovascular and neurodegenerative disease such as inflammatory pathways, which are
intimately connected in heart and brain disease.
1.2. Heart and Brain Interconnectedness in Disease
There are currently few therapeutics for cardiovascular and neurodegenerative diseases that provide suitable efficacy and minimal side effects, creating ideal conditions for
drug repurposing. Not only are cardiovascular and neurodegenerative diseases difficult
to treat, but treatment options remain limited, and many drugs do not cease progression
nor achieve remission of the disease state. Considerable progress has been made in recent
years to understand the molecular determinants of cardiovascular disease, which encompasses a wide variety of disorders such as endothelial dysfunction, atherosclerosis and
pulmonary arterial hypertension, and neurodegenerative disorders, including Parkinson’s
and Alzheimer’s diseases [30,31] Cardiovascular disease and neurodegenerative disorders
share a common trait of inflammation as a central component to the pathogenic process.
Targeting inflammatory processes with repurposed drugs can have a multitude of beneficial effects for patients with diseases of both the heart and brain. Currently, repurposed
drugs are being used in studies associated with two cardiovascular related diseases that
include endothelial dysfunction and pulmonary arterial hypertension. In neurodegener-

Pharmaceuticals 2021, 14, 573

4 of 19

ative diseases, repurposed drugs are being studied for the treatment of autophagy and
neuroinflammation (Table 2).
Table 2. Examples of drug or drug targets that have been identified using computational methods.

Drug or Target

Target Pathology

Research Method

Reference

kinase inhibitors

Alzheimer’s disease

machine learning

[32]

dopaminergic
agonists

Parkinson’s disease

machine learning

[24]

beta-secretase 1
inhibitors

Alzheimer’s diseases

data mining

[33]

GIST-T1 cells

Gastrointestinal
stromal tumor

High-throughput synergy
screening

[34]

2. Targeting Endothelial Dysfunction in Cardiovascular Disease
Cardiovascular diseases including atherosclerosis, coronary artery disease, and arrhythmias that eventually lead to myocardial infarction and/or stroke. Ischemic events
such as these are the leading cause of death in the world [35]. Pharmacological intervention
of cardiovascular diseases is provided by statins, beta-blockers, and angiotensin-converting
enzyme inhibitors. In more advanced cases, surgical intervention may be necessary. The
medications for cardiovascular disease target high cholesterol and low-density lipoprotein
levels, and hypertension. There is an emerging field of research to discover small molecule
inhibitors for alternative pathways aimed at the disruption of heart disease progression [36].
There is a robust market for pharmaceutical companies to create drugs to treat disorders,
but the potential for repurposing already FDA-approved drugs constitutes a desirable
alternative to discovery since these medications have been deemed safe enough for patient
use and thus lower the clinical trial barrier for novel therapeutic usage.
Endothelial dysfunction is especially important in cardiovascular disease because it
is a leading contributor to cardiac events. The endothelium is characterized by the cells
of the tissue lining the various organs of the body, including the arteries and lymphatic
system. The endothelium plays a major role in blood flow and constriction by facilitating
the synthesis and degradation of vasodilating factors, such as nitric oxide (NO), arachidonic
acid metabolites and reactive oxygen species (ROS) [37]. Endothelial dysfunction occurs
when the endothelium fails to function properly. Namely, that the endothelium dysfunctions in the formation of vasodilating factors. Endothelial dysfunction is a component
of atherosclerosis, which is characterized by the hardening and narrowing of the arterial
walls, and hyperlipidemia, or high lipid concentrations in the blood.
Three drugs have been investigated for their potential to treat diseases of endothelial
dysfunction that will be discussed here include colchicine, traditionally used to treat
gout; methotrexate, an immunosuppressant and chemotherapy drug; and Tocilizumab, an
immunosuppressant used to treat severe rheumatoid arthritis.
2.1. Colchicine
Colchicine is a secondary metabolite from the plants Gloriosa superba and Colchicum
autumnale, which is toxic when ingested [38]. The current FDA and EMA approved
use for colchicine is to treat gout, an inflammatory form of arthritis common in people
with high levels of uric acid in their blood. Due to its anti-inflammatory properties,
colchicine is currently under investigation as a potential endothelial dysfunction drug.
Endothelial dysfunction is a characteristic of cardiovascular disease that leads to an increase
in macrophages, T lymphocytes, and growth factors that contribute to atherosclerotic lesion
formation associated with atherosclerosis [39–42]. The same inflammation inhibition
mechanism that permits colchicine to be effective against gout, may also be applicable to
the treatment of patients with early stages of atherosclerosis [43,44].
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ing it to dihydrobiopterin in the aorta [54,55]. This leads to hypertension, hyperlipidemia
and induces endothelial dysfunction, because tetrahydrobiopterin is necessary as a cofactor
required for the synthesis of NO [56].
There is contradicting evidence for methotrexate use as an endothelial dysfunction
drug. On the one hand, there is data that suggests methotrexate reduces inflammation,
while methotrexate also appears to lead to endothelial dysfunction. Therefore, more
studies must be performed to determine the true mechanism of action for methotrexate
on the vascular endothelium if it is to be used to treat endothelial dysfunction. There are
currently 2140 clinical trials listed under the National Library of Medicine’s clinical trial
database, with methotrexate being evaluated for the treatment of everything from ectopic
pregnancy, to schizophrenia, to alopecia and cancer. It appears that in many pathologies
where inflammation is a principal concern, or where immunomodulation is of utility,
methotrexate may provide benefit.
2.3. Tocilizumab
Tocilizumab (TCZ) is an IL-6 inhibitor and recombinant monoclonal antibody used in
rheumatoid arthritis treatment since obtaining EMA approval in 2009 and FDA approval
in 2010 [57]. TCZ binds IL-6 and blocks JAK/STAT signaling to prevent the production
of pro-inflammatory molecules [57,58]. It is currently being investigated for the treatment
of endothelial dysfunction due to its anti-inflammatory properties. This is because RA is
often listed as a co-morbidity in approximately 39–50% of atherosclerosis-related deaths,
with endothelial dysfunction presented in many RA patients [59]. One hypothesis is that
the release of networks of chromatin and granules (NETs) into the extracellular space, a
common occurrence in both RA and endothelial function. TCZ was found to alleviate
symptoms in endothelial dysfunction in a human clinical study [58].
3. Targeting Pulmonary Arterial Hypertension
Pulmonary arterial hypertension (PAH) is a relatively rare condition, affecting approximately 10–52 people per million population, characterized by the narrowing of the
pulmonary arteries [60,61]. Left untreated, pulmonary arterial hypertension leads to the
buildup of pressure on the right side of the heart when blood vessels in the lungs are
diseased, causing the arteries to become increasingly narrow with time, and right-sided
heart failure, often resulting in premature death [62,63]. While the direct cause of pulmonary arterial hypertension is unknown, a set of factors including liver disease, HIV
infection, intravenous drug use, autoimmune disorders, and others are suspected to be
culpable. For pulmonary arterial hypertension, there are several drugs under investigation
for use that are in clinical trials [64]. Of these, two drugs—Anakinra and Ubenimex—target
inflammatory processes specifically.
3.1. Anakinra
Anakinra was approved for use in rheumatoid arthritis by the FDA in 2001 and
EMA in 2002 but is currently under investigation and has undergone Phase I clinical trial
studies for novel use in PAH [64,65]. Anakinra, an interleukin-1 (IL-1) receptor protein
antagonist analogue, is recombinantly expressed in E. coli and then administered via
subcutaneous injection. The proposed mechanism of action for PAH, shown in mice, is to
block perivascular macrophage recruitment in pulmonary artery smooth muscle cells [66].
In an inflammatory response pathway, IL-1b binds to IL-1 receptor (IL-1R) and recruits the
myeloid differentiation primary response protein 88 (MyD88) and induces IL-1 synthesis
via NFκB activation. In this study, the goal was to investigate whether this pathway played
a role in the progression of PAH [66]. First, it was determined that in both the lung tissue
taken from patients with PAH as well as mice with PAH, there were increased expression
levels of both IL-1R and MyD88. Hypoxic wild-type mice treated with anakinra (20 mg/kg
per day) were shown to have lower severity in PAH symptoms, namely, right ventricular
systolic presser and hypertrophy, than untreated mice. These findings provided evidence
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that anakinra may be a good potential treatment for PAH. Furthermore, the pilot Phase I
clinical study (clinicaltrials.gov: NCT03057028) done with treatment of PAH by anakinra
found promising results.
3.2. Tadalafil
Tadalafil is currently used to treat erectile dysfunction and benign prostatic hyperplasia, and was approved by the EMA in 2008 and FDA in 2009 for treatment of pulmonary
arterial hypertension [64,67]. Tadalafil is a phosphodiesterase type-5 (PDE5) inhibitor [68].
PDE5 mRNA levels are mostly found in the cerebellum, kidney, pancreas, and rat lung
tissues, which may be indicative of human mRNA localization [69]. The result, here, is such
that cyclic guanosine monophosphate (cGMP) concentrations are elevated and thus facilitate the NO pathway, namely vasodilation [70]. In brief, cGMP binds to PDE5 and increases
catalytic activity approximately 10-fold, leading to a decrease in protein kinase G (PKG)
stimulation and ultimately affecting vascular tone and growth in erectile dysfunction [71].
The inhibition of PDE5 leads to elevated cGMP and NO levels.
The 16-week, double-blind, phase III clinical trial that led to the approval of tadalafil
for pulmonary arterial hypertension treatment consisted of 405 patients diagnosed with
PAH. The patients were given a prescribed dosage of tadalafil or a placebo, and their
performance to walk for six minutes was evaluated based on the distance they covered [70].
The findings of the study identified that an oral dosage of 40 mg per day of tadalafil
could improve exercise capability by an average of 33 m in patients with pulmonary
arterial hypertension versus the placebo patients. Dosage was weight-dependent, though
all patients weighed an average of 75 ± 22 kg in this study. Of the 357 patients that
participated in a long-term study with tadalafil, 295 of them continued treatment. While
this study, along with other clinical trials, showed vast improvements in patients with
pulmonary arterial hypertension, the molecular mechanism by which tadalafil acts as a
therapeutic has yet to be elucidated.
4. Modulating Autophagy in Neurodegeneration
Neurodegenerative disorders are devastating, irreversible conditions that are characterized by the loss of neurons in the brain. In many cases, the onset of neurodegeneration
associated with diseases including Parkinson’s and Alzheimer’s disease, is sporadic with
no known genetic or environmental cause [72,73]. Given the absence of a causative agent,
there are no disease-modifying treatments available, and existing drugs serve only to
treat symptoms in an attempt to slow the effects of disease progression [74]. There exists
an important need for treatment options that prevent, slow, or stop the progression of
neurodegenerative disorders.
Neurodegenerative disorders can affect different areas of the nervous system and
cause patients to exhibit different symptoms depending on the disease; however, many
share important characteristics outside the gradual loss of neurons over time. For example, Alzheimer’s disease (AD), Parkinson’s disease (PD), Amyotrophic Lateral Sclerosis
(ALS) and Huntington’s disease all exhibit protein aggregate pathology in the form of
neurofibrillary tangles, Lewy bodies, inclusion bodies, and mutant Huntingtin aggregates,
respectively [75]. It is believed that these aggregates are toxic and play a role in neuronal
death. Neurodegenerative disorders are also commonly associated with aberrant activation
of the innate and adaptive immune systems in the central nervous system. Currently, significant research efforts are focused on targeting the mechanism by which these aggregates
are removed by cell, namely autophagy. Alternatively, efforts also include studying the
role inflammation plays in these disorders [71].
Autophagy is a cellular process responsible for maintaining protein homeostasis in
the cell. While there is more than one mechanism of autophagy, macro-autophagy is
the most studied and best understood type. For this reason, we will focus on macroautophagy (hereafter referred to as autophagy). In autophagy, cytoplasmic materials such
as proteins, metabolites, and organelles are engulfed by membrane-bound vesicles known
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(PIP3), which is a direct inhibitor of autophagy and allows more calcium to enter the cell,
creating a positive feedback loop. By blocking cytoplasmic calcium, there is a net reduction
in PIP3 and an induction of autophagy [78].
Felodipine activity to induce autophagy by blocking L-type calcium channels was
identified as favorable in a screen of drugs assessed in primary mice neurons [79]. Out of
nine calcium channel blockers, felodipine showed the greatest increase in autophagosomes
and autophagolysosomes. The efficacy of felodipine has been further assessed in zebrafish
models of tauopathy, a class of neurodegenerative disease involving the aggregation of Tau
protein in the human brain, mouse models of Huntington’s disease, and mouse models
of PD [79]. In mice, felodipine has the ability to ameliorate signs of Huntington’s disease
over a treatment period of 12 weeks and resulted in improved clearance of alpha-synuclein,
the main component of Lewy bodies. Twenty-two B6HD mice, a Huntington’s disease
model, were treated with felodipine starting in their sixth week from birth, and were
tested for grip strength, wire maneuvering and tremors, every two weeks from age 7 to
19 weeks. Felodipine-treated mice were reported to have better grip strength from week
11–19 and a reduction in tremors from weeks 17–19, when compared to vehicle-treated
control mice [79]. Likewise, A53T alpha-synuclein mice, a common PD mouse model,
were shown to have improved grip strength, increased neuron numbers in the substantia
nigra (the area of the brain affected by PD), and a reduction in insoluble alpha-synuclein, a
protein that comprises Lewy bodies. In zebrafish, a rho: tau model was used to emulate
cell death associated with the aggregation of Tau protein commonly associated with AD.
In this model, wild-type human tau protein is expressed in rod photoreceptors and causes
cell death. Felodipine successfully rescued rod cell death, but failed to do so in zebrafish
lacking atg7, a vital autophagy gene, suggesting the effect of felodipine on these cells is
dependent on autophagy [79].
While felodipine has shown promise as a potential new treatment for neurodegeneration, cautious skepticism is advised due to how recent the studies have been conducted
and the scope of studies has been limited to preclinical models of disease. Human clinical
trials and efficacious dosage regimens remain to be conducted. Due to differences between
human and mouse physiology, felodipine is metabolized much quicker in mice. As a result,
the mice in this study were exposed to transient exposures of felodipine that are two orders
of magnitude higher than the dosage indicated for use as an antihypertensive drug in
humans. It is possible that the required dosage is so high that deleterious side-effects may
preclude human treatment. Finally, the models used in this work were only successful in
showing that felodipine can clear protein aggregates; the studies did not include the full
disease course or its progression.
4.2. Lonafarnib
Lonafarnib is a promising drug that has passed phase two clinical trials for the
treatment of progeria, a genetic disorder causing accelerated aging in children, and phase
three clinical trials for the treatment of hepatitis delta virus infections [80]. Lonafarnib is
a farnesyltransferase inhibitor that prevents prenylation, the addition of a lipid group to
the cysteine residues of proteins. In hepatitis delta infections, prenylation is required for
the assembly and packaging of new viral particles [79]. By inhibiting prenylation, fewer
viral particles are created. In progeria, a genetic mutation causes Lamin A to be truncated
and form progerin. Lamin A is an important part of the nuclear membrane structure and
may be required for the repair of double-stranded DNA breaks [81]. When progerin is
formed instead, it is prenylated and cannot incorporate into the nuclear membrane. By
inhibiting farnesyltransferase and prenylation, the instability of the nuclear membrane can
be rescued [81].
Interestingly, lonafarnib shows promise as an inducer of autophagy and might be a
possible therapeutic to treat tauopathy. In the cell, autophagy is regulated by the mechanistic target of rapamycin (mTOR) kinase, also commonly referred to as FK506-binding
protein 12-rapamycin-associated protein 1 (FRAP1). When mTOR is active, autophagy
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is inhibited. mTOR itself is regulated by the G-protein, Rheb, which is functional when
localized to the cell membrane via a fatty acid chain tether. Farnesyltransferase inhibitors,
such as lonafarnib disrupt the prenylation of Rheb and prevent its localization to the inner
cell membrane. Without Rheb in the proper position, mTOR cannot be activated, resulting
in an upregulation of autophagy [82].
Lonafarnib has been shown to induce autophagy in primary mice fibroblast cells as
well as improving symptoms in mice models of dementia. In a study by Hernandez et al.,
transgenic NIH3T3 mouse fibroblast cells were used to show efficacy in inducing autophagy [83]. NIH3T3 cells were used to perform a fluorescent assay that can determine
the rate of autophagy [82]. NIH3T3 cells treated with increasing doses of lonafarnib exhibited dose-dependent increases in autophagolysosomes suggesting a lonafarnib-mediated
increase in autophagy. Furthermore, Tg4510 mice, used as a dementia model displaying behavioral impairments associated with dementia, were treated with lonafarnib starting at 10
weeks of age with oral administration of lonafarnig at 80 mg/kg per day. At 20 weeks, mice
were assessed for nest-building behaviors. Treated mice displayed an improvement in nest
shredding, a trait associated with these mice. Lonafarnib was also able to ameliorate the
circling behavior attributed to this model, but not reverse it after already manifesting. Due
to these findings, it was concluded that lonafarnib cannot reverse existing tau pathology,
but can prevent it from worsening [83].
While lonafarnib is indeed a promising drug, it is important to consider that this drug
is still in relatively early stages of the drug discovery pipeline. It has not yet been approved
by the FDA and is not clinically available. It is also important to note that the successful use
of this drug as a treatment for dementia would also be hindered by the fact that lonafarnib
cannot reverse the damage done by tauopathy. Because of this, lonafarnib may be essential
in patients with early diagnoses. Studies on the inhibition of prenylation of proteins should
be performed to determine if lonafarnib may have any off-target effects, as there are many
proteins that need to be prenylated to function correctly. It is likely that in the case of
progeria, the life-saving effect seen by long-term use of this drug outweighs any potentially
harmful side effects, but the same cannot be inferred for dementia.
5. Inflammation and NRF2 as a Target in Neurodegeneration
Chronic inflammation in the brain is associated with many neurodegenerative disorders including multiple sclerosis, Parkinson’s disease, macular degeneration, cutaneous
T-cell lymphoma, obstructive sleep apnea and adult brain glioblastoma and rheumatoid
arthritis [71]. It has been hypothesized that the innate immune response and chronic
inflammation of the brain mediated by microglia and astrocytes have a role in the onset of
neurodegeneration, and there is interest in studying therapeutics to reduce neuroinflammation. As an example, nuclear factor (erythroid-derived 2)-like2 (NRF2) is a transcription
factor that regulates the expression of detoxifying enzymes and antioxidant genes including
NAD(P)H quinone oxidoreductase 1, heme oxygenase-1(HO-1), glutathione S-transferase
(GST) genes, and UDP-glucuronosyltransferase (UGT) genes. NRF2 is inhibited by KEAP1
under normal conditions, but NRF2 is activated under stressful conditions. Under normal conditions, KEAP1 binds to NRF2 and mediates its degradation via the ubiquitinproteasome system. However, under conditions of oxidative stress, KEAP1 releases NRF2
allowing it to upregulate any number of antioxidant genes. One such gene is HO-1. HO-1
catalyzes the degradation of heme into carbon monoxide (CO), free iron, and biliverdin as
well as directly upregulating anti-inflammatory cytokines and inhibiting pro-inflammatory
cytokines. In addition to these points, CO inhibits NFκB, a signaling protein responsible
for promoting pro-inflammatory cytokines [84]. Activation of the NRF2 signaling pathway,
which is shown in Figure 5, has a net anti-inflammatory effect. Dimethyl fumarate and
exemestane are two drugs that could be repurposed for treatment of inflammation due to
aberrant NRF2 signaling pathways.
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fumarate and exemestane are two drugs that could be repurposed for treatment of inflammation due to aberrant NRF2 signaling pathways.
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DMF was approved by the FDA and EMA in 2014 as a medication to treat relapsing
forms of multiple sclerosis (MS) at 240 mg 2–3 times per day [87,88]. Multiple sclerosis
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is an autoimmune disease that is characterized by the degradation of the myelin sheath
surrounding nerves, resulting in pain and motor function impairment. DMF is metabolized
to monomethyl fumarate in the body, which acts as an agonist of the nAChR, resulting in
activation of the NRF2 pathway leading to a reduction in the inflammation that exacerbates
demyelination. More recently, DMF has been found to activate this same anti-inflammatory
pathway in PD patients, providing a promising treatment option for neurodegeneration
that appears to work in mouse models of α-synucleinopathy at 100 mg/kg [89]. In PD,
DMF has demonstrated a neuroprotective effect by ameliorating mitochondrial dysfunction
and upregulating mitochondrial biogenesis by blocking neurotoxicity in wild-type, but not
NRF2 knockout mice [90].
On par with other immunomodulation treatments, DMF does not have a singular
mechanism of action or one biochemical pathway that is targeted with administration.
Rather, it is believed that DMF has multiple targets and exerts a spectrum of biological
effects that lead to the therapeutic experienced by MS patients treated with DMF [86].
As shown in in vitro studies, DMF partially exerts anti-inflammatory action with the ability
to increase the production of interleukin-4 (IL-4) and IL-5 when added to cultures of
stimulated peripheral mononuclear blood cells [91]. These cytokines are conducive to
producing and promoting a Th2 immune response. The perturbation away from the Th1
response was also replicated in dendritic cells. The polarization of the immune response
away from Th1 and toward the Th2 profile is a probable mechanism for DMF function as
an immunomodulator. There is also evidence that DMF stimulates the native anti-oxidative
stress machinery in cells. The antioxidative response is activated by NRF2, the primary
transcription factor for genes associated with the anti-oxidative response. DMF has been
shown to enhance the nuclear translocation of NRF2, and thus activating transcription of
associated genes. The effect DMF has on the NRF2 pathway is likely a profound contributor
to the mechanism of action [87].
In a study by Lastres-Becker et al., rAAV6-α-synuclein NRF2+/+ and NRF2−/− mice
were treated with DMF for one and three weeks followed by additional treatments every
other day for eight weeks [89]. One day before sacrifice, the mice were assessed for motor
asymmetry via the elevated body swing test. The NRF2−/− mice displayed significantly
increased contralateral body torsion compared to the NRF2+/+ mice [92]. Additionally,
DMF was assessed for its effect on signs of inflammation at the tissue level. One sign
of inflammation in Parkinson’s disease is the increase of microglia and astrocytes in the
basal ganglia known as microgliosis and astrocytosis, respectively. In order to test the
effect of DMF on these inflammatory markers, NRF2+/+ mice treated with DMF displayed
significant decreases in astrocytosis and microgliosis compared to the NRF2−/− mice.
In the brain, microglia can express one of two phenotypes, a pro-inflammatory, IL-1β
and inducible nitric oxide synthase (iNOS)-producing phenotype and anti-inflammatory,
IL-4 and sphingosine kinase 2-producing phenotype. DMF was shown to mediate the
conversion of the pro-inflammatory phenotype to the anti-inflammatory phenotype in
mouse BV2 microglial cells. Cells treated with DMF displayed increased levels of IL-4
mRNA in a time-dependent manner [89]. DMF was also shown to have a neuroprotective
effect on BV2 cells in studies where the cells were pretreated with DMF and then exposed
to α-synuclein. Untreated cells had an induction of IL-1β and iNOS whereas pretreated
cells displayed lower pro-inflammatory marker induction. Based on these findings, NRF2
appears to be a potentially useful target for Parkinson’s disease treatment, and DMF may
bring us one step closer to a disease-modifying drug [92].
A survey of clinical trial data yielded that DMF has been or is being investigated for
efficacy in treating the following disease states: primary progressive multiple sclerosis,
relapsing-remitting multiple sclerosis, age-related macular degeneration, cutaneous T-cell
lymphoma, obstructive sleep apnea, adult brain glioblastoma and rheumatoid arthritis.
While there is a diversity of pathologies being investigated with the administration of
DMF, inflammation arises as a shared theme in these clinical trials. Immunomodulation,
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downregulation of proinflammatory cytokines, the effect of DMF on T-cell regulation, and
DMF exerts in vitro could be of utility in treating a myriad of diseases [93].
5.2. Exemestane
Exemestane was approved by the FDA and EMA in 1999 and is an aromatase inhibitor
for use on estrogen-dependent breast cancers, especially in post-menopausal women at
a dosage of 25 mg per day [94,95]. Exemestane treats breast cancer in post-menopausal
women by preventing the synthesis of estrogen via the inhibition of the aromatization
step of androgens into estradiol, a precursor of estrogen. Without estrogen, these estrogendependent cancers’ growth and spread is inhibited. Exemestane was identified as a
potential treatment for Parkinson’s disease through a screen aiming to find compounds that
activate HO-1 [96]. Exemestane was found to be one of the most effective compounds in the
screen. The proposed mechanism for treating Parkinson’s disease is different than that of
treating breast cancer, where exemestane inhibits the formation of estrogen from androgen
during the rate-limiting step of aromatase conversion [93,97]. In this sense, exemestane
acts as an upregulator of NRF2 expression, a transcription factor responsible for producing
antioxidant enzymes in order to circumvent the degeneration of dopaminergic neurons
due to high amounts of oxidative stress from ROS such as NO [94,98].
In a study by Son et al. (2017), exemestane was validated in BV2 microglial cells and
in MPTP mouse models of Parkinson’s disease. BV2 cells were tested for NRF2 protein
levels, HO-1 and NQO1 mRNA levels, and iNOS and IL-1β levels following exemestane
treatment [94]. NRF2 expression was elevated 4.4-fold, suggesting exemestane-mediated
activation. Likewise, the expression of NRF2 downstream genes increased with exemestane
treatment, while inflammatory marker levels decreased. Taken together, these results
signify a possible reduction of inflammation by exemestane. In the same study, exemestane
was also evaluated in a mouse model of Parkinson’s disease. Mice were treated with MPTP,
a neurotoxin that kills dopaminergic neurons and attempts to simulate the death of neurons
in Parkinson’s disease. The mice were then co-administered with exemestane orally (1,
10, or 20 mg/kg), three times a day, every day for seven days. Following treatment, the
mice were sacrificed. Immunostaining was performed for tyrosine hydroxylase, a selective
marker expressed by dopaminergic neurons. Mice co-treated with exemestane exhibited a
42% reduction in the loss of dopaminergic neurons caused by MPTP [94].
DMF and exemestane both show enticing results as potential new treatments for
Parkinson’s disease; however, the exact molecular target of either drug remains unknown.
The Parkinson’s disease model studies performed with DMF and exemestane are still
preclinical, limiting any interpretation of results regarding potential efficacy in humans.
One concern that may be raised for exemestane experiments has to do with the MPTP
mouse model. The addition of a toxin does not necessarily recapitulate Parkinson’s disease
progression because the neurons die all at once instead of gradually over time as they would
in human disease progression. Additionally, the results from the Son et al. study seem to
contradict previous reports that estradiol has a neuroprotective effect in PD [94]. However,
estradiol and its structural analog, exemestane, exhibit their neuroprotective qualities
through JNK and NRF2 pathways, respectively. This would necessitate further studies on
the effects of estradiol and its inhibition in the context of PD. Another consideration that
must be made is that the experiments conducted on mice for both drugs were done over a
relatively short period of time. The DMF treatments lasted eight weeks and the exemestane
tests were done for seven days. It will be necessary to discover how long-term treatments
affect the progression of Parkinson’s disease in more relevant model systems up to and
including human trials.
6. Conclusions
The benefit of repurposing drugs that were previously approved by the FDA removes
many of the time and financial barriers for bringing a drug to market. FDA approval is a
good indication of a drug’s effectiveness and safety in clinical trials, which is indicative of
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a good outcome for the use of a drug for a different purpose. Because a drug can take anywhere from 8–12 years from its initial discovery to the market, drug repurposing can reduce
this time significantly. The repurposing of drugs to treat cardiovascular and neurodegenerative diseases is an emerging and promising field of study. Treatments for inflammatory
diseases including vascular endothelial dysfunction, pulmonary arterial hypertension,
multiple sclerosis, Parkinson’s and Alzheimer’s, using repurposed drugs like colchicine,
methotrexate, tocilizumab, felodipine, lonafarnib, dimethyl fumarate and exemestane may
prove to be an effective strategy to address the treatment gap for untreatable ailments.
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